<DOC>
	<DOCNO>NCT02637973</DOCNO>
	<brief_summary>The effect empagliflozin treatment hepatocellular lipid content , liver energy metabolism body composition investigate multicentre , prospective , placebo-controlled , double-blind , randomize , 2-arm parallel , interventional exploratory pilot study patient newly diagnose type 2 diabetes .</brief_summary>
	<brief_title>Effects Empagliflozin Liver Fat Content , Energy Metabolism Body Composition Patients With Type 2 Diabetes</brief_title>
	<detailed_description>In multicentre , prospective , placebo-controlled , double-blind , randomize , 2-arm parallel , interventional pilot study HCL intramyocellular lipid ( IMCL ) quantify 1H magnetic resonance ( MR ) spectroscopy . Hepatic ATP inorganic phosphate ( Pi ) concentration assess 31P MR spectroscopy ( 1 ) . Whole-body hepatic insulin sensitivity metabolic flexibility measure combine hyperinsulinemic-euglycemic pancreatic clamp test isotopic dilution 6,6-2H2 glucose indirect calorimetry show ( 2 ) . Abdominal fat distribution quantify MR image . Newly diagnose patient type 2 diabetes ( T2D ) randomly allocate daily 25 mg empagliflozin ( EMPA ) placebo 24 week computer-generated random sequence mask treatment assignment . Participants visit clinical research center baseline , 12 week 24 week MRS metabolic examination , include blood sample hepato- adipocytokines . Anthropometric parameter ( body weight , waist circumference , total body fat , blood pressure ) glycemic control ( HbA1C , fast blood glucose , FBG ) assess baseline monitoring visit every 4 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>age 18 75 year BMI &lt; 45 kg/m2 know diabetes duration 7 year 6 % ≤HbA1c≤8 % drug naïve previous antihyperglycemic treatment one month washout period treatment oral glucose lower drug ( previous treatment thiazolidinedione ( TZD ) drug allow ) obtain write informed consent uncontrolled hyperglycaemia screening ( glucose level ≥240 mg/dl overnight fast , confirm second measurement ) acute coronary syndrome , stroke transient ischemic attack within 3 month prior consent previous low limb amputation severe low limb infection/ulceration within 3 month prior consent liver disease include chronic viral hepatitis ( B C ) , alcohol abuse , hemochromatosis , alpha1 antitrypsin deficiency , autoimmune hepatitis , Wilson 's disease , primary sclerosing cholangitis primary biliary cirrhosis , liver cirrhosis etiology AST ALT &gt; 3 x ULN positive result hepatitis B ( HBsAG ) , hepatitis C ( HCVAB ) , HIV 1 2 test impair kidney function ( estimate glomerular filtration rate [ eGFR ] &lt; 60 mL/min/1.73m2 ) screen structural functional urogenital abnormality , predispose urogenital infection gastrointestinal surgery induce chronic malabsorption history cancer ( except basal cell carcinoma ) treatment cancer within 5 year blood dyscrasia disorder cause haemolysis unstable erythrocyte treatment antiobesity drug 3 month prior consent treatment immunomodulatory drug ( oral steroid , antihistamine ) change dosage thyroid hormone within 6 week consent pregnancy , lactation period metal magnetic implant , device object inside body , MRI compatible ( accord MRT safety checklist Appendix 11.3 ) claustrophobia cigarette smoking ( nonsmoker &lt; 1year ) , alcohol consumption ( male &gt; 30 g/d , female &gt; 20g/d ) drug abuse psychiatric disease nightworker circumstance allow normal daynight rhythm hypersensitivity empagliflozin ( drug similar chemical structure ) drug compound pharmaceutical preparation interaction expect amiloride , furosemide , indapamide , spironolactone , torasemide , triamterene use antiNASH drug ( vitamin E , ursodeoxycholic acid , Sadenosylmethionine , betaine , silymarin , gemfibrozil , antiTNF therapy , probiotic ) 3 month prior randomization woman childbearing potential use two adequate method contraception include barrier method highly efficacious nonbarrier method person kind dependency investigator employ sponsor investigator person hold institution legal official order participation another trial last 10 week randomization plan participation trial period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>